Subscribe

Stay Informed. Stay Ahead.

Subscribe to receive curated updates, expert insights, and practical education—delivered straight to your inbox.

Get timely coverage on new approvals, case-based discussions, conference highlights, and practical tools for everyday practice in community oncology and hematology.

Subscribe
*
Skip to main content
OncUpdates
  • Conferences
    • ASCO GU
    • ASCO GI
    • ASH
    • SABCS
    • ESMO
    • WCLC
    • ASCO
  • Videos & Podcasts
    • Challenging Cases
      • Hematology
      • Lung Cancer
      • Breast Cancer
      • GU Oncology
    • New Approvals
      • Hematology
      • GI Oncology
      • GU Oncology
      • Lung Cancer
      • Breast Cancer
    • Tox Check
      • GI Oncology
      • GU Oncology
      • Lung Cancer
      • Breast Cancer
      • Hematology
    • Treatment Algorithms
      • Breast Cancer
      • Dermatology
      • Hematology
      • Lung Cancer
      • Ovarian Cancer
      • Head and Neck Cancers
  • Clinical Insights
    • GU Oncology
      • Bladder Cancer
      • RCC
    • GI Oncology
      • Gastroesophageal Cancer
      • Gastric/GEJ Cancer
    • Breast Cancer
      • Early HR+
      • Metastatic HR+
    • Hematology
      • Polycythemia Vera
    • Lung Cancer
      • SCLC
      • NSCLC
  • Resource Centers
    • Pancreatic Cancer
    • Metastatic Breast Cancer
  • Articles
    • GI Oncology
    • Hematology
    • Lung Cancer
  • Events
  • Conferences
    • ASCO GU
    • ASCO GI
    • ASH
    • SABCS
    • ESMO
    • WCLC
    • ASCO
  • Videos & Podcasts
    • Challenging Cases
      • Hematology
      • Lung Cancer
      • Breast Cancer
      • GU Oncology
    • New Approvals
      • Hematology
      • GI Oncology
      • GU Oncology
      • Lung Cancer
      • Breast Cancer
    • Tox Check
      • GI Oncology
      • GU Oncology
      • Lung Cancer
      • Breast Cancer
      • Hematology
    • Treatment Algorithms
      • Breast Cancer
      • Dermatology
      • Hematology
      • Lung Cancer
      • Ovarian Cancer
      • Head and Neck Cancers
  • Clinical Insights
    • GU Oncology
      • Bladder Cancer
      • RCC
    • GI Oncology
      • Gastroesophageal Cancer
      • Gastric/GEJ Cancer
    • Breast Cancer
      • Early HR+
      • Metastatic HR+
    • Hematology
      • Polycythemia Vera
    • Lung Cancer
      • SCLC
      • NSCLC
  • Resource Centers
    • Pancreatic Cancer
    • Metastatic Breast Cancer
  • Articles
    • GI Oncology
    • Hematology
    • Lung Cancer
  • Events

Explore Videos, Articles & More

RCC

Clinical data, expert insights, and treatment advancements presented at the ASCO Genitourinary Cancers Symposium renal cell carcinoma sessions, focusing on practice-informing updates.

Home / Conferences / ASCO GU / RCC
Positive Trials for Belzutifan in Earlier Treatment Lines for RCC
Positive Trials for Belzutifan in Earlier Treatment Lines for RCC

Michael Serzan, MD, Toni Choueiri, MD

Radiotherapy Strategies in Metastatic Clear Cell Renal Cell Carcinoma
Radiotherapy Strategies in Metastatic Clear Cell Renal Cell Carcinoma

Michael Serzan, MD, Shreyas Kalantri, MD

Cabozantinib and Novel Doublets in Advanced RCC
Cabozantinib and Novel Doublets in Advanced RCC

Nicholas Simon, MD, Sumanta Pal, MD, FASCO

First-Line Treatment Strategies in Metastatic Renal Cell Carcinoma
First-Line Treatment Strategies in Metastatic Renal Cell Carcinoma

Andre Kydd, MD, PhD, Nicholas Simon, MD

Evolving Standards in Renal Cell Carcinoma: Practical Insights from ASCO GU
Evolving Standards in Renal Cell Carcinoma: Practical Insights from ASCO GU

Adriana Penate, MD

OncUpdates

Empowering oncology professionals with The latest insights, breakthroughs, And expert opinions

Quick Links

  • About Us
  • Upcoming Events
  • Follow on X
  • Follow on LinkedIn
  • Follow on YouTube

Legal

  • Terms of Use
  • Privacy Policy
  • Cookie Settings
  • Authors
  • Contact Us

Subscribe to Our Newsletters


Property of SignifyMD LLC, All Rights Reserved 2026 SignifyMD LLC PO Box 512, Brielle, NJ 08730


Oncology Resources | Hematology Support | Community Oncology